Sarepta develops and commercializes ribonucleic acid targeted therapeutics for the treatment of neuromuscular diseases.Read more
Moderna is Sarepta's biggest rival. Moderna was founded in 2010, and is headquartered in Cambridge, Massachusetts. Moderna competes in the Biotechnology industry. Moderna generates $2.2B more revenue vs. Sarepta.
Alnylam is one of Sarepta's top competitors. Alnylam's headquarters is in Cambridge, Massachusetts, and was founded in 2002. Like Sarepta, Alnylam also works within the Pharmaceuticals sector. Alnylam generates 99% of Sarepta's revenue.
Sarepta's revenue is the ranked 3rd among it's top 10 competitors. The top 10 competitors average 478.7M. Over the last four quarters, Sarepta's revenue has grown by 7%. Specifically, in Q1 2021's revenue was $146.9M; in Q4 2020, it was $145.1M; in Q3 2020, it was $143.9M; in Q2 2020, Sarepta's revenue was $137.4M.